Frontier Biotechnologies Inc. (SHA:688221)

China flag China · Delayed Price · Currency is CNY
20.42
+1.20 (6.24%)
At close: Mar 10, 2026
102.78%
Market Cap 7.65B
Revenue (ttm) 143.67M
Net Income (ttm) -261.72M
Shares Out 374.58M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,064,330
Average Volume 15,043,950
Open 19.40
Previous Close 19.22
Day's Range 19.31 - 20.48
52-Week Range 7.16 - 29.98
Beta 1.08
RSI 38.77
Earnings Date Mar 31, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and me... [Read more]

Sector Healthcare
Founded 2002
Employees 524
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688221
Full Company Profile

Financial Performance

In 2025, Frontier Biotechnologies's revenue was 143.67 million, an increase of 10.96% compared to the previous year's 129.47 million. Losses were -261.72 million, 30.0% more than in 2024.

Financial Statements

News

There is no news available yet.